Applications

1313 – Bone mineral density analyses using Dual Energy X-Ray Absorptiometry (DXA) in breast cancer patients receiving aromatase inhibitor treatment

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type New application
  • Pre-PASC consultation -
  • Pre-MSAC consultation -
  • Outcome Not supported

Application details

Reason for application

-

Service or technology in this application

This proposal is for the provision of an MBS item for bone densitometry by DXA for women with breast cancer who receive, or are being considered for, treatment with aromatase inhibitors.

Medical condition this application addresses

In hormone receptor-positive breast cancer the proliferation of mammary carcinoma cells is dependent on oestrogen. Common therapies for hormone receptor positive breast cancer include aromatase inhibitors and tamoxifen. The aromatase inhibitors have a negative impact on bone density due to the inhibition of overall oestrogen production within the body

Application documents

PICO confirmation

Assessment report

Public summary document – November 2014

Public summary document – July 2015

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Meetings to consider this application

  • PASC meeting: 
    • 16 to 17 August 2012
    • 13 to 14 December 2012
  • ESC meeting: 
    • 12 to 13 June 2014
    • 11 to 12 June 2015
  • MSAC meeting: 
    • 26 to 28 November 2014
    • 30 to 31 July 2015